T Cell News and Research

Latest T Cell News and Research

Intravitreal ranibizumab shows little benefit after hemorrhage

Ranibizumab given intravitreally offers no clear benefit in the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy, a randomized clinical trial indicates.

8 Feb 2013

Tumor necrosis factor receptor 2 involved in renal decline in diabetes

Researchers have found that circulating levels of tumor necrosis factor receptor 2 are independently associated with the development of chronic kidney disease in nonobese Japanese patients with Type 2 diabetes.

8 Feb 2013

Milk thistle constituent shows promising skin protection properties

Silibinin, a key component of milk thistle seeds, can help protect against skin damage caused by ultraviolet B radiation, show study findings published in Molecular Carcinogenesis.

8 Feb 2013

Oral eosinophilic ulcers ‘a self-limiting, reactive condition’

A review of patients with oral eosinophilic ulcers suggests that the lesions should be considered a reactive, local condition rather than a CD30+ lymphoproliferative disorder.

8 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Studies to identify molecular causes and preventive and therapeutic strategies for Parkinson's

On the fourth floor of Wichita State University's McKinley Hall, biochemistry professor Kandatege Wimalasena and his group of doctoral and undergraduate students are hard at work researching Parkinson's disease (PD) - the second-most common neurodegenerative disease, affecting 1 to 2 percent of people older than 60.

7 Feb 2013

Key details of how TRF2 protein performs crucial chromosome-protecting function

We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.

7 Feb 2013

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.

7 Feb 2013

Basis of antidepressant drugs and electroconvulsive therapy found

Through a series of investigations in mice and humans, Johns Hopkins researchers have identified a protein that appears to be the target of both antidepressant drugs and electroconvulsive therapy. Results of their experiments explain how these therapies likely work to relieve depression by stimulating stem cells in the brain to grow and mature.

7 Feb 2013

Glimmer of hope for imatinib-resistant GIST

The monoclonal antibody SR1 can significantly inhibit gastrointestinal stromal tumor cell growth, report researchers in the Proceedings of the National Academy of Sciences.

7 Feb 2013

New method can determine seriousness of cancer prognosis with 80% certainty

The number of incorrect cancer prognoses can be halved with computerised image analysis. In three years time, the method can be used on patients with bowel cancer, ovarian cancer and prostate cancer.

6 Feb 2013

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics, Inc. today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas.

6 Feb 2013

Surgery could boost chemotherapy outcomes in canine TCC

Dogs that undergo curative surgery for transitional cell carcinoma before initiating a combination of doxorubicin and piroxicam therapy have significantly longer median overall survival than their counterparts not pretreated surgically, report researchers.

6 Feb 2013

Start palliative care early for optimum results

Palliative care provided early in the ambulatory care setting varies with the trajectory of patients’ disease and is complementary to medical management, show study results.

6 Feb 2013

Tumor suppressor mutant may predict poor outcome in breast cancer

An oncogenic variant of the Krüppel-like family 6 tumor suppressor gene appears to play a role in driving breast cancer metastasis and may be a prognostic marker for poor patient outcome, report researchers.

6 Feb 2013

More than £6M funding awarded to enhance development of biopharmaceuticals

More than £6M of funding has been awarded to enhance the development of biopharmaceuticals. In total £6.5M will fund 12 projects to deliver commercially important results, such as industrial-scale production of antibodies, stem cell preservation at room temperature, biopharmaceutical production using microbes and commercial scale stem cell therapy.

6 Feb 2013

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States.

6 Feb 2013

Non-coding RNA MALAT1 influences lung cancer metastasis

The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides.

6 Feb 2013

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.

5 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013